Health Catalyst Analyst Ratings
Strong Recovery and Expansion Forecast Justifies Buy Rating for Health Catalyst
Health Catalyst Analyst Ratings
Health Catalyst Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Curis (CRIS), Health Catalyst (HCAT) and Innate Pharma SA (OtherIPHYF)
Health Catalyst Analyst Ratings
Strong Q1 Performance and Strategic Ignite Platform Launch Underpin Buy Rating for Health Catalyst (HCAT)
Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT), Bluebird Bio (BLUE) and Viatris (VTRS)
Buy Rating Affirmed for Health Catalyst Amid Solid Growth and Strategic Financial Management
KeyBanc Keeps Their Hold Rating on Health Catalyst (HCAT)
Analysts' Top Healthcare Picks: Health Catalyst (HCAT), Sartorius (GB:0NIQ)
R1 RCM, Health Catalyst Downgraded as KeyBanc Reviews Health-tech Space
What 7 Analyst Ratings Have To Say About Health Catalyst
Cantor Fitzgerald Reiterates Overweight on Health Catalyst, Maintains $16 Price Target
Health Catalyst Analyst Ratings
Health Catalyst Analyst Ratings
Buy Rating on Health Catalyst: Strategic Innovation and Client Growth Poised to Drive Performance
Barclays Issues a Buy Rating on Health Catalyst (HCAT)
RBC Capital Remains a Hold on Health Catalyst (HCAT)
Maintaining Buy Rating on Health Catalyst: Strong Sales Pipeline and Margin Outlook Offset Slower Growth Forecast